Abstract
Sarcoidosis is a rare granulomatous disease that can affect any organ. It leads to an increased risk of metabolic syndrome and insulin resistance, due to biochemical pathways involved in low-grade inflammation in both diseases. The aim of our retrospective case–control study was to evaluate the utility of triglyceride-glucose (TyG) index, a surrogate of insulin resistance, for metabolic assessment of sarcoidosis patients. A cohort of 90 sarcoidosis patients and a cohort of 90 control subjects were enrolled. Clinical, anamnestic, and biochemical data were collected. Results showed that TyG index values were higher in the sarcoidosis cohort than in the control group (p < 0.001), even after excluding the influence of diabetes and metabolic syndrome (p = 0.018). In the sarcoidosis cohort, TyG index was not correlated with clinical phenotyping (p = 0.358), gender (p = 0.139), radiological stage (p = 0.656), glucocorticoids cumulative dose (p = 0.682) or treatment regimen (p = 0.093), while significant positive correlations with waist circumference (p < 0.001), systolic and diastolic pressure (p = 0.041 and p = 0.029, respectively), Framingham score (p = 0.007) were found. Receiving operating characteristics curve analysis identified a TyG index optimal cut-off value of 8.64 (66.7% sensitivity, 77.8% specificity, area under the curve -AUC- 75%, 95% confidence interval -CI- 65–85, p < 0.001) to detect metabolic syndrome and a cut-off value of 8.69 (64.1% sensitivity, 70.6% specificity; AUC 67%, 95% CI 55–78, p = 0.007) to detect an intermediate cardiovascular risk according to Framingham risk score. Concluding, TyG index can be considered a useful tool for the metabolic assessment of sarcoidosis patients, given its capacity to predict metabolic syndrome and cardiovascular risk.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Sarcoidosis is a rare chronic multisystemic disease of unknown etiology characterized by the presence of non-necrotizing granulomas in the involved organs. Respiratory system is one of the most frequently affected sites, although any organ can be virtually involved [1]. The prevalence of sarcoidosis varies depending on the geographical area, ranging from 1 to 5 per 100,000 in South Korea, Taiwan and Japan to 140–160 per 100,000 in Sweden and Canada; the incidence is likewise variable, ranging from 11.5 per 100,000 in Sweden to 0.5–1.3 per 100,000 in East Asia [2]. Clinical presentation is heterogeneous and generally characterized by cough, chest discomfort, dyspnea, low-grade fever, tiredness, weight loss, and night sweats; a completely asymptomatic course of the disease is also possible [3]. Diagnosis is based on histological evidence of non-necrotizing granulomas of the involved organs, after excluding other causes of granulomatous disorders, and in addition to typical radiological and clinical findings [4]. First-line therapy involves the use of oral corticosteroids, whereas azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, cyclophosphamide, leflunomide or hydroxychloroquine can be used as second-line drugs; finally, third-line choices are represented by anti-tumor necrosis factor-a (TNF-a) antibodies, such as infliximab or adalimumab [3].
Sarcoidosis shows a bidirectional relationship with metabolic syndrome, obesity, and insulin resistance: in fact, on the one hand, sarcoidosis patients have a higher risk of developing metabolic syndrome and insulin resistance [5], while an increase in body mass index (BMI) and weight gain lead to a higher risk of developing sarcoidosis [6]. This correlation could find an explanation in the low-grade chronic inflammatory state characterizing both diseases [5], thus leading to an increase in cardiovascular (CV) risk in sarcoidosis patients [7].
In the context of dysmetabolism, triglyceride-glucose (TyG) index, which is calculated from fasting glucose and triglycerides, is interestingly emerging as a useful surrogate of insulin resistance [8,9,10]: it showed a higher accuracy than homeostasis model assessment of insulin resistance (HOMA-IR) in predicting metabolic syndrome [11] and a certain predictive value in terms of cardiovascular disease (CVD) [12, 13].
Moving from these premises and considering the importance of assessing metabolic risk in sarcoidosis patients, the aim of the present study was to possibly confirm the previous evidence regarding a higher prevalence of metabolic syndrome in patients with sarcoidosis, and thus to investigate the utility of TyG index in sarcoidosis clinical setting.
Methods
Study population
We conducted a retrospective case–control study through the enrollment of a cohort of subjects with an established diagnosis of sarcoidosis—defined as “cases” and a cohort of control subjects defined as “controls”.
Inclusion criteria for cases were the presence of a firm diagnosis of sarcoidosis according to international ATS/ERS/WASOG criteria [14] and age greater than 18 years; exclusion criteria were the presence of other causes of granulomatous disorders and age under 18 years.
For control group inclusion criteria were the absence of any pulmonary, intestinal, hepatic, rheumatological, neoplastic disease or other chronic conditions (except for metabolic comorbidities namely metabolic syndrome, dyslipidemia, arterial hypertension, and diabetes) and age greater than 18 years; exclusion criteria were the presence of any chronic condition not allowed by the inclusion criteria and age under 18 years.
Regarding “cases”, eligible subjects were consecutively selected among patients monitored at our regional Sarcoidosis Referral Centre in Bari (South Italy) from March 2020 to May 2023. In the case of controls, age- and sex-matched eligible subjects were selected among patients who were visited through our internal medicine day-service regimes from November 2022 to April 2023. Selection of cases and controls was made according to the established inclusion and exclusion criteria. For both cases, subjects with incomplete clinical, instrumental, and biochemical data were excluded. A final population of 90 consecutive cases and 90 age- and sex-matched controls was enrolled.
Data collection
For each enrolled patient, data about age, sex, smoking habits, and comorbidities was collected; the diagnosis of metabolic syndrome was made referring to the International Diabetes Federation diagnostic criteria [15].
Waist circumference values (expressed in cm), body mass index values (expressed in Kg/m2), systolic, and diastolic arterial pressure values (expressed in mmHg) were also collected. The following laboratory findings were examined: fasting glucose, total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), and triglycerides (TG); all these data were expressed in mg/dL.
Framingham risk score (FRS) was evaluated for CV risk assessment [16]. TyG index was also calculated using the following formula: Ln [TG (mg/ dL) × fasting glucose (mg/dL)/2] [17].
Moreover, for sarcoidosis patients’ additional information inherent to radiological classification according to Scadding criteria [18] and phenotypical stratification according to GenPhenReSa [19] were collected. Treatment regimen data, including glucocorticoid (GC) cumulative dose, when available, was obtained. Illness duration was calculated as the time elapsed between diagnosis and the enrollment data.
For both cohorts, data collection was made considering the information related to the most recent outpatient visit.
Statistical analysis
Results were expressed as median and interquartile range (IQR). Since data did not show a normal distribution, comparisons between pairs of variables and multiple comparisons were performed using Mann–Whitney and Kruskal Wallis tests, respectively. The Spearman’s Rho test was used for correlation analysis. Contingency tables were analyzed by Chi-square test. Receiving operating characteristic (ROC) curve analysis was used to assess the predictive capacities of the TyG index. A p-value less than 0.05 was considered statistically significant. Statistical analysis was obtained using IBM SPSS Statistics version 26 and GraphPad Prism version 9 softwares.
Results
General features of the sample
90 sarcoidosis patients and 90 controls were enrolled. Body mass index (BMI) values were lacking for 37 controls. No significant differences in gender, age, BMI, and smoking status were found among the two cohort; regarding metabolic comorbidities, the prevalence of diabetes and dyslipidemia was similar among the two groups, while arterial hypertension and metabolic syndrome were more represented in the sarcoidosis group. Regarding the latter, about half of the patients took specific therapy for the disease at the time of the enrollment with a median GC cumulative dose of 5115.62 mg; interestingly, GC cumulative dose values were not significantly different depending on the presence or absence of arterial hypertension or metabolic syndrome (p = 0.103, and p = 0.417, respectively). Most of sarcoidosis patients showed pulmonary involvement with a prevalence for the second radiological stage (Table 1).
Case–control comparison
Sarcoidosis group showed TC, LDL-c, fasting glucose, and TG values significantly higher than the control group (p = 0.037, p = 0.019, p = 0.006, and p = 0.001, respectively), while no significant differences were found in terms of HDL-c (p = 0.671). Regarding clinical data, only systolic blood pressure values were significantly higher in the sarcoidosis group than in controls (p = 0.035); finally, Framingham risk score showed similar values among the two groups (p = 0.866).
Regarding the TyG index, the analysis showed significantly higher values in the sarcoidosis group than in the control one (p < 0.001). Intriguingly, the data continued to be significant even if the major determinants of insulin resistance (namely metabolic syndrome and diabetes) were excluded from the analysis in both groups (p = 0.018) (Table 2).
Analysis of the TyG index in the sarcoidosis cohort
Deepening the behavior of the TyG index in the sarcoidosis cohort (Table 3), results showed a non-significant correlation with illness duration (R = 0.001, p = 0.989) or age (R = 0.179, p = 0.092). Moreover, the TyG index was independent of GenPhenReSa clinical phenotyping (p = 0.358), gender (p = 0.139) and radiological stage (p = 0.656). Regarding the treatment regimen, the TyG index still showed an independent trend from the need for a pharmacological treatment at the time of the enrollment (p = 0.093) and from the GC cumulative dose (R = 0.040, p = 0.682). On the other hand, the TyG index presented a significant positive correlation with waist circumference (R = 0.377, p < 0,001), systolic and diastolic blood pressure (R = 0.216, p = 0.041 and R = 0.230, p = 0.029, respectively); a significant positive correlation between TyG index and Framingham score was also found (R = 0.284, p < 0.01).
Moreover, TyG index values were significatively higher in the subgroup of sarcoidosis with metabolic syndrome than in sarcoidosis patients without metabolic syndrome (8.77, IQR 8.52–8.98, and 8.38, IQR 8.10–8.63, respectively; p < 0.0001, Fig. 1). This evidence suggests that the TyG index was closely related to metabolic syndrome also in this specific cohort of patients.
Ability of TyG index to predict metabolic syndrome and cardiovascular risk in sarcoidosis cohort
ROC curve analysis was performed to test the ability of the TyG index to predict metabolic syndrome among sarcoidosis patients: according to the Youden index, a TyG index optimal cut-off value of 8.64 (66.7% sensitivity, 77.8% specificity) with an area under the curve (AUC) of 75% (95% confidence interval 65–85, p < 0,001) was found (Fig. 2).
In the light of the positive and significant correlation between TyG index and Framingham score, ROC curve analysis (Fig. 3) was performed also to test the ability of TyG index to predict cardiovascular risk: according to Youden index, a TyG index optimal cut-off value of 8.69 (64.1% sensitivity, 70.6% specificity; AUC 67%, 95% confidence interval 55–78, p < 0.01) was able to identify a Framingham risk score equal or greater than 10, that is equivalent to an almost intermediate cardiovascular risk [20].
Discussion
Sarcoidosis is a chronic inflammatory disease that can affect metabolic homeostasis, exposing patients to a higher risk of developing metabolic syndrome [5]. In the first place, both diseases share the expression of a proinflammatory cytokines pathway that includes interleukin-(IL)-6, IL-8, IL-12, and tumor necrosis factor-alpha (TNF-α): the latter is one of the most important cytokines involved in metabolic syndrome, dyslipidemia, and insulin resistance, whereas IL-6, IL-8 and IL-12 also promote metabolic syndrome [21]. In the second place, a certain susceptibility to develop dysmetabolism can be considered as an adverse effect of glucocorticoids long-term therapy [22].
For these reasons, sarcoidosis patients show a higher risk of developing atherosclerosis and CVD than the general population [7, 23]; this evidence is confirmed even when considering a subclinical level of atherosclerotic damage [24, 25].
In light of these considerations, the importance of a metabolic assessment is crucial for CVD prevention in the context of a sarcoidosis clinical setting.
The goal of our retrospective study was to possibly confirm a higher prevalence of metabolic syndrome in sarcoidosis patients and to investigate the utility and applicability of the TyG index, a surrogate of insulin resistance, to quickly identify sarcoidosis patients at high risk of metabolic syndrome.
In the first place, results showed TyG index values significantly higher in the sarcoidosis cohort than in controls, so highlighting a higher predisposition in sarcoidosis to develop metabolic syndrome. Intriguingly, the TyG index was higher in the sarcoidosis group even when subjects with diabetes and metabolic syndrome were excluded from the analysis. This evidence suggests that sarcoidosis could play an independent role in determining metabolic syndrome because of a constant, chronic low-grade inflammation. To support this hypothesis, our results showed that the TyG index was not correlated with age or illness duration, neither to phenotypical features of the disease, such as gender, different organ involvement or radiological stage. Moreover, TyG index values were not significantly different between treated and not-treated subjects and were not influenced by glucocorticoid cumulative dose: in other words, therapy seemed to be unable to shape the trend of the TyG index. This last evidence is also supported by the analysis of the trend of GC cumulative dose in two sub-cohort of sarcoidosis patients: those affected by arterial hypertension and those affected by metabolic syndrome. Our results showed that GC cumulative dose median values did not differ significantly depending on the presence or absence of these metabolic comorbidities. These results further suggest that metabolic comorbidities seemed to be influenced by the presence of the sarcoidosis itself, rather than pharmacological therapy taken by patients.
These results are coherent with a recent study that underlines how metabolic syndrome may be more frequent in sarcoidosis even before treatment is started: analyzing 133 newly diagnosed sarcoidosis patients, 133 age- and sex-matched controls, and 51 untreated rheumatoid arthritis subjects, authors found that metabolic syndrome was more common in sarcoidosis patients than controls (odds ratio 5.3, p < 0.001) and similar to rheumatoid arthritis group; moreover, triglycerides, glucose, waist circumference, and diastolic blood pressure values of female sarcoidosis patients were significantly higher than controls [21].
Moreover, our results showed that among sarcoidosis patients, the TyG index was significantly higher in subjects with metabolic syndrome: this finding confirms the close correlation between the TyG index and metabolic syndrome even in the specific clinical context of sarcoidosis.
Afterwards, the capacity of the TyG index to predict metabolic syndrome has been evaluated through the ROC curve analysis. With a view to improving its predictive capabilities, results suggested a potential role of the Tyg index in identifying metabolic syndrome in sarcoidosis patients: according to our findings, an optimal cut-off value of 8.64 has proved to detect metabolic syndrome similar to the previous evidence in the general population[11].
Another important consideration arises from correlation studies: indeed, the TyG index showed a statistically significant positive correlation with Framingham risk score and a potential ability to screen for cardiovascular risk: a TyG index cut-off value of 8.69 showed the capacity to detect an almost moderate cardiovascular risk in sarcoidosis group.
For all these features, the TyG index can be considered a valid tool to screen sarcoidosis patients for metabolic comorbidities, allowing physicians to detect high cardiovascular-risk patients and setting a personalized follow-up plan.
To our knowledge, our study explores for the first time the utility of the TyG index in a sarcoidosis clinical setting. Results pointed out that it can be considered a useful tool for the metabolic assessment of sarcoidosis patients because it showed a considerable capacity for screening for metabolic syndrome and cardiovascular risk. TyG index could be implemented in daily clinical practice from the perspective of a holistic evaluation of sarcoidosis patients, so considering the metabolic features of the disease that can potentially modulate its outcome. We retain that TyG index evaluation should be routinely considered for the assessment of sarcoidosis patients: in the case of high TyG index values, physicians could suspect the presence of an insulin-resistance state and consequently deepen the metabolic assessment of the patient, requiring further laboratory test such as oral glucose tolerance test. TyG index can so allow a quick achievement of crucial information to plan a careful therapeutic strategy: for example, a significant and gradual increase of TyG index in patients taking corticosteroids should alert the physician about the worsening of metabolic homeostasis, suggesting the need for introduction of steroid-sparing drugs such as methotrexate or azathioprine. From the other hand, basal high TyG index values in treatment-naïve patients could lead physicians to avoid the use of corticosteroids as the first therapeutic choice whenever possible. Finally, the TyG index could help to identify patients deserving of a screening and possible treatment of metabolic comorbidities.
The present study has some limitations. The first one is related to the retrospective design of the study which may have led to a selection bias. In detail, it could be due to the exclusion from the enrollment of subjects with incomplete collectible data and to the enrollment of the controls subjects among patients who underwent to a medical examination for a wide variety of clinical reasons; therefore, controls cohort could not be considered fully representative of the general population. For this reason, our results may have been partially affected by this methodological feature; thus, it would be desirable to confirm our findings through further perspective observational studies.
Another limitation of the study arises from the analysis of ROC curve results, which suggests the need to further deepen the TyG index behaviour in the sarcoidosis cohort, eventually improving the diagnostic accuracy of the TyG index in predicting metabolic syndrome and cardiovascular risk. In this regard, the enrollment of a greater sample size could be useful to obtain more accurate results.
With a view of an emerging need for precision medicine, clinical phenotyping could be helpful to understand prognosis and to choose the most appropriate therapeutic and follow-up planning. For example, in the context of the therapeutic field, Rana et al. found that a peripheral neutrophil-to-lymphocyte ratio could be considered a useful laboratory biomarker related to disease activity and the need for treatment [26].
However, given the high susceptibility of sarcoidosis patients to develop metabolic comorbidities, a stratification based on metabolic features should also be considered. Moreover, it can represent a challenging field of research: since sarcoidosis and metabolic syndrome partially share common pathogenetic biochemical pathways, it could be interesting to evaluate if metabolic features can somehow affect pharmacological therapeutic response. In this regard, the TyG index could be considered for further studies for the possible development of a metabolic-based phenotypical stratification model. In detail, clinicians could deepen if the metabolic homeostasis of the patient is somehow related to specific phenotypical features of the disease such as organ involvement, duration of clinical remission, response to pharmacological therapy or the impact on symptoms and quality of life. This approach eventually could help to identify a new stratification model of sarcoidosis patients capable to predict the prognostic impact and to suggest the most appropriate treatment.
In conclusion, the TyG index can be considered a promising useful tool for the metabolic assessment of sarcoidosis patients. Further studies are needed to better define how to introduce it in daily clinical practice. Moreover, the TyG index can be considered an innovative item around which new research direction can be traced, with the aim of deepening the impact of metabolic comorbidities on the prognosis of sarcoidosis patients.
Data availability
All data supporting the findings of this study are available from corresponding author on reasonable request.
References
Rizzi L, Sabbà C, Suppressa P (2022) Sarcoidosis and autoimmunity: In the depth of a complex relationship. Front Med (Lausanne) 9:991394
Arkema EV, Cozier YC (2020) Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm 26(5):527–534
Jain R, Yadav D, Puranik N, Guleria R, Jin J (2020) Sarcoidosis: causes, diagnosis, clinical features, and treatments. J Clin Med 9:1081
Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J (2019) Sarcoidosis. Nat Rev Dis Prime 5(1):45
Yıldız Gülhan P, Güleç Balbay E, Erçelik M, Yıldız Ş, Yılmaz MA (2020) Is sarcoidosis related to metabolic syndrome and insulin resistance? Aging Male 23(1):53–58
Cozier YC, Coogan PF, Govender P, Berman JS, Palmer JR, Rosenberg L (2015) Obesity and weight gain in relation to incidence of sarcoidosis in US black women: data from the Black Women’s Health Study. Chest 147(4):1086–1093
Ungprasert P, Crowson CS, Matteson EL (2017) Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J 49(2):1601290
Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6:299–304
Guerrero-Romero F, Simental-Mendia LE, Gonza’lez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandezonzalez SO et al (2010) The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 95:3347–3351
Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X (2014) Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol 13:146
Son DH, Lee HS, Lee YJ, Lee JH, Han JH (2022) Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis 32(3):596–604
Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, Ma J, Zhao Y, Zhu W, Wang J (2022) Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 21(1):124
Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, Yang H, Ren LB, Qi W, Li WY, Zhang R, Xu JH (2020) Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol 19(1):80
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/world Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis 16(2):149–73
Holt RIG (2005) International Diabetes Federation re-defines the metabolic syndrome. Diabetes Obes Metab 7(5):618–620
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–47
Lim J, Kim J, Koo SH, Kwon GC (2019) Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: An analysis of the 2007–2010 Korean National Health and Nutrition Examination Survey. PLoS One. 14(3):e0212963
Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 2(5261):1165–72
Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O’Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O’Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J (2018) Phenotypes of organ involvement in sarcoidosis. Eur Respir J 51(1):1700991
Sohn C, Kim J, Bae W (2012) The framingham risk score, diet, and inflammatory markers in Korean men with metabolic syndrome. Nutr Res Pract 6(3):246–253
Işık AC, Kavas M, Tezcan ME (2022) Metabolic syndrome may be more frequent in treatment-naive sarcoidosis patients. Z Rheumatol 83:154–159
Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM 3rd, Hunder GG, Gabriel SE (2007) Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthr Rheum 57(2):279–86
Bargagli E, Rosi E, Pistolesi M, Lavorini F, Voltolini L, Rottoli P (2017) Increased risk of atherosclerosis in patients with sarcoidosis. Pathobiology 84(5):258–263
Rizzi L, Coppola C, Cocco V, Sabbà C, Suppressa P (2023) Cardiovascular risk in rare diseases: a prognostic stratification model in a cohort of sarcoidosis patients. Intern Emerg Med 18(5):1437–1444
Yılmaz HEB, Yılmaz M, Erol T, Şen N, Ünsal ZE, Kara S, Habeşoğlu MA, Akçay Ş (2020) Evaluation of subclinical atherosclerosis with carotid intima-media and epicardial fat thickness in patients with sarcoidosis. Turk Thorac J 21(3):174–179
Rana GD, d’Alessandro M, Rizzi L, Bergantini L, Cameli P, Vozza A, Sestini P, Suppressa P, Bargagli E (2021) Clinical phenotyping in sarcoidosis management. Sarcoidosis Vasc Diffuse Lung Dis 38(2):e2021007
Acknowledgements
P.S. is funded under the National Recovery and Resilience Plan (NRRP), Mission 4, Component 2 Investment 1.3—Call for tender No. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union – NextGenerationEU; Project code PE00000003, Concession Decree No. 1550 of 11 October 2022 adopted by the Italian Ministry of University and Research, CUP D93C22000890001, Project title “ON Foods—Research and innovation network on food and nutrition Sustainability, Safety and Security – Working ON Foods”. A.M. is funded by the Italian Association for Cancer Research—AIRC IG 2019 Id 23239, by MIUR-PRIN 2022H9MPZ5 “Metabolic hits in the road to colon cancer” and by National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3—Call for tender No. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union – NextGeneration EU; Project code PE00000003, Concession Decree No. 1550 of 11 October 2022 adopted by the Italian Ministry of University and Research, CUP D93C22000890001, Project title “ON Foods—Research and innovation network on food and nutrition Sustainability, Safety and Security – Working ON Foods”. L.C. is funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3—Call for tender No. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union – NextGeneration EU; Award Number: Project code PE0000015, Concession Decree No. 1243 of 2 August 2022 adopted by the Italian Ministry of University and Research, CUP H33C22000680006, Project title “Ageing well in an ageing society—A novel public-private alliance to generate socioeconomic, biomedical and technological solutions for an inclusive Italian ageing society– AGE-IT”.
Funding
Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.
Author information
Authors and Affiliations
Contributions
L.R. and C.C.: conceptualization and statistical analysis, wrote original draft; R.R., L.C. and Y.H..: collected data; A.M. and P.S.: coordinated the study design, wrote the original draft, and supervised data collection and discussed study results. All authors revised the initial draft and provided comments regarding important intellectual contributions. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee of Azienda Ospedaliero—Universitaria Policlinico di Bari (Bari, Italy).
Human and animal rights
This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Luigi Rizzi and Chiara Coppola authors share first authorship.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rizzi, L., Coppola, C., Hbaidi, Y. et al. Role of triglyceride-glucose index in metabolic assessment of sarcoidosis patients. Intern Emerg Med (2024). https://doi.org/10.1007/s11739-024-03609-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11739-024-03609-4